By a News Reporter-Staff News Editor at Women's Health Weekly -- Fresh data on Oncology are presented in a new report. According to news reporting out of Albany, New York, by NewsRx editors, research stated, "The aim was to evaluate tetraiodothyroacetic acid (tetrac), a thyroid hormone analog of l-thyroxin, conjugated to poly(lactic-co-glycolic acid) nanoparticles (T-PLGA-NPs) both in vitro and in vivo for the treatment of drug-resistant breast cancer. The uptake of tetrac and T-PLGA-NPs in doxorubicin-resistant MCF7 (MCF7-Dx) cells was evaluated using confocal microscopy."
Our news journalists obtained a quote from the research from Albany Medical College, "Cell proliferation assays and a chick chorioallantoic membrane model of FGF2-induced angiogenesis were used to evaluate the anticancer effects of T-PLGA-NPs. In vivo efficacy was examined in a MCF7-Dx orthotopic tumor BALBc nude mouse model. T-PLGA-NPs were restricted from entering into the cell nucleus, and T-PLGA-NPs inhibited angiogenesis by 100% compared with 60% by free tetrac. T-PLGA-NPs enhanced inhibition of tumor-cell proliferation at a low-dose equivalent of free tetrac. In vivo treatment with either tetrac or T-PLGA-NPs resulted in a three- to five-fold inhibition of tumor weight. T-PLGA-NPs have high potential as anticancer agents, with possible applications in the treatment of drug-resistant cancer."
According to the news editors, the research concluded: "Original submitted 2 May 2012; Revised submitted 21 November 2012."
For more information on this research see: Tetraiodothyroacetic acid-conjugated PLGA nanoparticles: a nanomedicine approach to treat drug-resistant breast cancer. Nanomedicine, 2013;8(12):1943-1954. Nanomedicine can be contacted at: Future Medicine Ltd, Unitec House, 3RD Floor, 2 Albert Place, Finchley Central, London, N3 1QB, England. (Elsevier - www.elsevier.com; Nanomedicine - www.elsevier.com/wps/product/cws_home/703416)
Our news journalists report that additional information may be obtained by contacting D.J. Bharali, Albany Medical College, Dept. of Med, Albany, NY 12208, United States. Additional authors for this research include M. Yalcin, P.J. Davis and S.A. Mousa (see also Oncology).
Keywords for this news article include: Albany, Therapy, New York, Oncology, Treatment, Nanoparticle, United States, Breast Cancer, Nanotechnology, Women's Health, Drug Resistance, Emerging Technologies, North and Central America
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC